[1] |
张波, 杨文英. 中国糖尿病流行病学及预防展望[J]. 中华糖尿病杂志,2019,11(1):7-10.
|
[2] |
张洁, 张妮娅. 300例老年糖尿病患者临床流行病学特点及诊治分析[J]. 解放军预防医学杂志,2018,36(5):609-612.
|
[3] |
阮婷, 徐晓. 老年人社区获得性肺炎的相关危险因素分析[J]. 中华老年医学杂志,2015,34(7):720-722.
|
[4] |
Dharmalingam M, Aravind SR, Thacker H, et al. Efficacy and safety of remogliflozin etabonate, a new sodium glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus: a 24-week, randomized, double-blind, active-controlled trial[J]. Drugs,2020,80(6):587-600.
|
[5] |
Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, et al. COVID-19 and diabetes: abidirectional relationship[J]. Clin Investig Arterioscler,2021,33(3):151-157.
|
[6] |
Liu Y, Wang Y, Ni Y, et al. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention[J]. Cell Metab, 2020,31(1):77-91.
|
[7] |
Farhan SS, Hussain SA. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus[J]. Diabetes Metab Syndr,2019,13(4):2457-2461.
|
[8] |
Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)[J]. Diabetes Obes Metab,2018,20(3):520-529.
|
[9] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志,2018,38(4):34-86.
|
[10] |
何新华. 社区获得性肺炎的诊治-2014指南[C]. 中华医学会急诊医学分会全国急诊医学学术年会,2014.
|
[11] |
孙静. 血糖糖化血红蛋白果糖胺指标在糖尿病中的临床应用[J]. 检验医学与临床,2009,6(9):694-694,696.
|
[12] |
袁丽萍, 张丽玲, 江淼, 等. 2型糖尿病合并感染多器官功能障碍综合征与干扰素调节因子5基因多态性的关联性[J]. 中华医院感染学杂志,2021,31(14):2099-2013.
|
[13] |
Lomonaco R, Godinez Leiva E, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening[J]. Diabetes Care, 2021,44(2):399-406.
|
[14] |
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease[J]. N Engl J Med,2021, 384(2):129-139.
|
[15] |
Acharya AB, Thakur S, Muddapur MV, et al. Systemic cytokines in type 2 diabetes mellitus and chronic periodontitis[J]. Curr Diabetes Rev,2018,14(2):182-188.
|
[16] |
Gonzalez DE, Foresto RD, Ribeiro AB. SGLT-2 inhibitors in diabetes: a focus on renoprotection[J]. Rev Assoc Med Bras,2020,66(Suppl 1): S17-S24.
|
[17] |
Rosenblatt R, Atteberry P, Tafesh Z, et al. Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis[J]. Dig Liver Dis,2021,53(4):445-451.
|
[18] |
韩波, 冯旰珠. 362例社区获得性肺炎患者临床特征及影响因素分析[J]. 南京医科大学学报:自然科学版,2014,34(6):772-776.
|
[19] |
刘春妮, 初卫江, 高爱芹, 等. 糖尿病合并不同临床表型肺部感染者的细菌谱分析[J/CD]. 中华实验和临床感染病杂志(电子版),2018,12(1):65-70.
|
[20] |
熊小芹, 罗光涛, 石亚军. 老年糖尿病患者合并社区获得性肺炎临床特点分析[J]. 川北医学院学报,2015,30(2):240-242,252.
|
[21] |
路玉李, 肖建东, 刘娜. 402例糖尿病患者弓形虫感染情况及其血糖及血脂指标变化分析[J]. 中国地方病防治杂志,2018,33(3):342, 344.
|
[22] |
Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication[J]. Diabetes Care,2020,43(7):1399-1407.
|
[23] |
Tuttle KR, Brosius FC 3rd, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the national kidney foundation[J]. Am J Kidney Dis,2021,77(1):94-109.
|
[24] |
Hartmann-Boyce J, Rees K, Perring JC, et al. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews[J]. Diabetes Care,2021,44(12):2790-2811.
|
[25] |
Khunti K, Knighton P, Zaccardi F, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England[J]. Lancet Diabetes Endocrinol,2021,9(5):293-303.
|
[26] |
Nevola R, Acierno C, Pafundi PC, et al. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management[J]. Minerva Med,2021,112(2):188-200.
|